ResMed (RMD) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.43 per share a year ago. These figures are ...
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre ...
Sydney: Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling ...
ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business model. I rate RMD a strong sell due to the imminent threat from Apnimed's ...
Resmed posts double-digit revenue and profit growth in Q2 FY26, declares dividend, and outlines plans for innovation. The Resmed CDI (ASX: RMD) share price is in focus after the company reported ...
SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed (RMD.N), opens new tab plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style ...
ResMed delivered a stronger December quarter, posting higher revenue and earnings as demand for its sleep and respiratory care devices continued to recover. The company’s results beat market ...
Now could be the time to buy ResMed Inc (ASX: RMD) shares. That's the view of analysts at Morgans, who have turned positive on the sleep disorder-focused medical device company following its ...
Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3% Income from operations increased 18%; non-GAAP ...
ResMed outlines 62%–63% gross margin target for fiscal 2026 amid double-digit growth in key segments
Sandercock provided updated guidance: "Looking forward and subject to currency movements, we now expect gross margin will be in the range of 62% to 63% for fiscal year 2026." SG&A expenses as a ...
ResMed Inc. (NYSE:RMD) presented its second-quarter fiscal year 2026 results on January 29, 2026, showcasing strong financial performance with revenue growth of 9% at constant currency. Despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results